In Non-Small Cell Lung Cancer (NSCLC), MET amplification drives EGFR-inhibitor resistance by activating EGFR-independent phosphorylation of ErbB3 and downstream activation of the PI3K/AKT pathway. This evidence concerns the gene EGFR and non-small cell lung carcinoma.